Pharos iBio Co.
Pharos iBio is a KOSDAQ-listed South Korean AI drug discovery company that uses its proprietary Chemiverse platform and federated learning (NVIDIA FLARE) to develop therapeutics for intractable diseases, serving global pharmaceutical partners such as Eli Lilly through licensing and AI development services.
- Company typePrivate
- Founded2016
- HeadquartersAnyang, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Pharos iBio Co. does
Pharos iBio Co. is a South Korea-based, KOSDAQ-listed (388870) AI-driven drug discovery company founded in 2016, headquartered in Anyang, with an 11-50 employee team focused on developing therapeutics for intractable diseases. The company builds and operates the Chemiverse platform, which combines proprietary drug discovery expertise with AI/ML predictive systems to identify and validate drug candidates. Its commercial posture is partnership-led, serving global pharmaceutical companies through AI services and platform collaboration arrangements; revenue is generated via AI drug development services and licensing/royalty structures tied to its proprietary platform, although pricing is not publicly disclosed.
The company's core technical differentiator is its integration with Eli Lilly's TuneLab AI platform via NVIDIA FLARE federated learning — the first such integration by a Korean AI drug discovery firm. This architecture enables collaborative model training across organizational boundaries without sharing raw molecular data, addressing pharmaceutical industry data privacy constraints. Chemiverse handles structured molecular and drug development data, supports multimodal AI workloads, and incorporates generative AI for candidate generation and predictive analytics for candidate validation. Distribution is via direct enterprise field sales to global pharma, augmented by conference-based partnering (e.g., BIO USA 2026).
Operationally, Pharos iBio has raised roughly 55 million USD cumulatively across five funding rounds between 2018 and 2025, led by Korean institutional investors including Company K Partners, Korea Investment Partners, and Korea Investment & Securities. The company completed a KOSDAQ listing (announced 2022 H2), and a 14% stock-price move in January 2026 reflected sector tailwinds from Insilico Medicine's Hong Kong listing. Management team composition, leadership hires, and granular revenue figures are not disclosed in available sources, and disclosed financials in the input carry unit/currency inconsistencies that limit revenue triangulation precision.
Pharos iBio Co. firmographics
Firmographics- Name
- Pharos iBio Co.
- Website
- https://pharosibio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pharos iBio is a KOSDAQ-listed South Korean AI drug discovery company that uses its proprietary Chemiverse platform and federated learning (NVIDIA FLARE) to develop therapeutics for intractable diseases, serving global pharmaceutical partners such as Eli Lilly through licensing and AI development services.
- Ownership category
- akta.pro rank
Pharos iBio Co. industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where Pharos iBio Co. is headquartered
LocationHeadquarters
- HQ city
- Anyang
- HQ country
- South Korea
- HQ region
- Asia
Markets served
Pharos iBio Co. business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales
Revenue model
- AI Drug Development Services: The company generates revenue through AI-powered new drug development services, providing pharmaceutical companies with AI/ML-driven drug discovery and development capabilities.
- Platform Collaboration Licensing: Revenue generated through strategic partnerships with major pharmaceutical companies, integrating proprietary Chemiverse platform with partners' AI systems for drug candidate validation.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Pharos iBio Co. product offering
Product offeringCore offering
Pharos iBio is a pharmaceutical company that develops drugs for intractable diseases using its proprietary Chemiverse AI platform, which combines in-house drug development expertise with AI/ML predictive systems. The company delivers AI-powered new drug development services and collaborates with global pharmaceutical firms to validate drug candidates and accelerate discovery timelines.
Product overview
Pharos iBio Co. operates as an AI-driven new drug development company offering a single integrated platform (Chemiverse) that combines the company's proprietary drug development expertise with external AI/ML predictive systems. The Chemiverse platform serves as the core technology offering, enabling drug candidate validation and collaboration with global pharmaceutical partners like Eli Lilly through integration with Lilly TuneLab.
Differentiator
Problem solved
Functional benefit
Products and services
- Chemiverse Platform Proprietary AI drug development platform that integrates Pharos iBio's drug development expertise with AI/ML predictive systems. It enables validation of drug candidates and collaboration with global pharmaceutical partners, including integration with Eli Lilly's Lilly TuneLab platform.
- AI-Powered New Drug Development Services Service offering that applies AI/ML-driven drug discovery and development capabilities to pharmaceutical partners, accelerating drug discovery timelines and reducing R&D costs for intractable disease targets.
Quantifiable outcome
- Stock price surged 14% in January 2026 amid positive AI drug development sentiment following Insilico Medicine's Hong Kong IPO success
Companies that use Pharos iBio Co.
Customer profileSegments2 records
Ideal customer profiles2 records
Pharos iBio Co. technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature2 records
Pharos iBio Co. partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eli LillycorePharos iBio signed a strategic cooperation agreement with Eli Lilly on June 9, 2026, to collaborate on Lilly TuneLab, Eli Lilly's AI drug development platform using federated learning technology based on NVIDIA FLARE. The partnership enables Pharos iBio to integrate its Chemiverse platform and drug development expertise with Eli Lilly's AI/ML predictive systems, marking the first domestic AI drug development firm to connect with Lilly TuneLab. Through this collaboration, Pharos iBio aims to validate drug candidates and enhance platform capabilities to strengthen global competitiveness.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Pharos iBio Co. competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-driven drug discovery company that recently completed a successful Hong Kong IPO. Directly comparable to Pharos iBio as a pure-play AI drug discovery platform targeting intractable diseases, and is the explicit market catalyst cited in Pharos's January 2026 stock surge.
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify novel therapeutics. Comparable to Pharos in using AI/ML predictive systems to accelerate drug candidate identification and validation, with a similar platform-partnering GTM motion.
- Schrödinger: Physics-based computational platform for drug discovery and materials science. Highly comparable as a software-plus-services AI drug discovery platform that licenses its predictive platform to global pharmaceutical companies, mirroring Pharos's Chemiverse licensing model.
- Exscientia: AI-driven precision medicine company focused on small molecule drug discovery. Comparable to Pharos in offering AI drug discovery services to pharma partners and pursuing a similar partner-centric commercial model.
- XtalPi: AI-powered drug discovery company combining quantum physics, AI, and robotics. Highly comparable as an Asia-based AI drug discovery platform pursuing global pharmaceutical partnerships and licensing arrangements, sharing Pharos's geographic positioning and GTM motion.
- Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning. Comparable to Pharos as an AI drug discovery platform that partners with global pharma on candidate validation and licensing.
- BenevolentAI: AI-driven drug discovery company applying machine learning to biomedical knowledge graphs. Comparable to Pharos in offering AI drug discovery capabilities to global pharmaceutical partners targeting complex diseases.
- Isomorphic Labs: Alphabet-owned AI drug discovery company leveraging DeepMind's AlphaFold technology. Comparable as a deep-tech AI drug discovery platform pursuing partnerships with major pharmaceutical companies for candidate development.
Broad incumbents
- Eli Lilly: Global pharmaceutical company and Pharos iBio's flagship TuneLab integration partner. Comparable as a strategic customer and platform partner — Lilly's TuneLab federated learning platform defines the integration architecture that Pharos's Chemiverse connects into.
Emerging players
- Aria Pharmaceuticals: AI-driven drug discovery company focused on complex diseases using causal machine learning. Comparable to Pharos as a smaller, emerging AI drug discovery platform pursuing pharma partnerships and targeting intractable therapeutic areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights5 records
Customer concentration
Pharos iBio Co. social profiles
Digital presencePharos iBio Co. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pharos iBio Co. leadership team
Management profileNumber of profiles
Pharos iBio Co. funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pharos iBio Co. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pharos iBio Co.
What does Pharos iBio Co. do?
Pharos iBio is a pharmaceutical company that develops drugs for intractable diseases using its proprietary Chemiverse AI platform, which combines in-house drug development expertise with AI/ML predictive systems. The company delivers AI-powered new drug development services and collaborates with global pharmaceutical firms to validate drug candidates and accelerate discovery timelines.
Is Pharos iBio Co. a public or private company?
Pharos iBio Co. is a private company. It is classified as public and is currently operating.
When was Pharos iBio Co. founded?
Pharos iBio Co. was founded in 2016. It employs 11 to 50 people.
Where is Pharos iBio Co. based?
Pharos iBio Co. is headquartered in Anyang, South Korea, in the Asia region.
How does Pharos iBio Co. make money?
Two revenue lines are on record. AI Drug Development Services are the primary driver. The others are platform Collaboration Licensing.
Who are Pharos iBio Co.'s main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Exscientia, XtalPi, Atomwise, BenevolentAI and Isomorphic Labs. Eli Lilly is listed as a broad incumbent. Aria Pharmaceuticals is listed as an emerging player.
Does Pharos iBio Co. have an API?
No public API is recorded for Pharos iBio Co..
What industry is Pharos iBio Co. in?
Pharos iBio Co.'s product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 32541 and its SIC code is 2834.